中国北京和日本长野，2020年11月30日-北京云顶国际基因生物技术有限公司（以下简称"云顶国际"）今日宣布，已与日本Ina Research Co., Ltd.（以下简称"INA"）签订商业代理协议，以拓展云顶国际在日本市场的业务。

作为世界上非常大的制药及销售市场之一，日本在创新药物研发方面享有盛誉。此次合作将把云顶国际创新的动物模型及国际水准的抗体药物发现评价平台及能力介绍给日本肿瘤免疫、自身免疫等各疾病领域的基础研究人员及新药研发人员。根据协议，INA作为云顶国际的销售代理及分销商，将负责云顶国际动物模型及临床前药理药效服务在日本的推广。

云顶国际创始人、董事长和CEO沈月雷博士表示：“INA和云顶国际都致力于助力合作伙伴的新药研发，双方在不同的药物开发阶段具有各自的优势，本次合作通过双方平台优势互补能带来更大的价值。我们相信通过双方团队的紧密合作，能为日本的客户及合作伙伴们提供一体化、整合性的新药研发平台。”

INA董事长和CEO Kenshi Nakagawa先生表示：“近年来我们感受到日本市场对于优质动物模型和临床前动物体内药效评价服务不断增长的需求，尤其是在免疫治疗领域。云顶国际的模型和服务能力已被美国、欧洲和中国的许多客户和合作伙伴包括多家跨国药企所认可。我们很高兴能够和云顶国际一起将这些先进的模型和高质量的服务介绍给日本企业和机构，加速新药创新。”

通过本次合作，云顶国际的产品和服务可以被快速推介给INA稳定的客户群体，包括顶尖药企、生物技术公司和研究机构。INA在10月初已经承办了一次在线宣讲，根据协议，INA将通过更多线上线下的推广活动来提升云顶国际在日本的知名度。

关于云顶国际

云顶国际是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地，以专注技术创新、持续新药产出、守护人类健康为使命。基于云顶国际自主研发并拥有完全独立知识产权的全人抗体RenMab^®、RenLiteTM、RenNanoTM小鼠，将单细胞抗体发现技术平台、高效的基因编辑模型开发平台、规模化动物模型供应平台、快速的动物体内外药效评价平台、强大的临床开发能力有机整合在一起，形成了独具特色、涵盖药物研发全流程的新药研发体系。公司成功战略转型为Biotech，未来将更聚焦于创新抗体药物研发。随着规模化抗体药物研发-“千鼠万抗”计划的实施，云顶国际将携手全球合作伙伴，共同加速新药研发。云顶国际总部位于北京，在江苏海门、美国波士顿、上海等地设有分支机构，全资子公司祐和医药专注于临床开发。

关于INA   

Ina Research 成立于 1974 年，总部位于日本长野县的伊纳市，在东京设有办事处。该公司的股票在JASDAQ交易所公开交易。Ina 主要为制药行业的客户进行分析和安全性和有效性研究，客户也包括生产农业化学品和医疗设备的公司。Ina的服务及研究领域包括药物依赖研究、中枢神经系统疗法的疗效研究、癌症研究、生殖和发育毒性研究以及动物模型。Ina与学术机构合作，在园区建立了一个研究中心，用以开展由日本医学研究开发机构资助的 CAR-T治疗的非临床安全研究。

Biocytogen Teams With Ina Research To Boost Presence In Japan

Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with Ina Research Co., Ltd. (hereinafter “INA”) to expand its business in Japan market.

As one of the world’s largest pharmaceutical markets, Japan has an established reputation for innovative drug research and development. The partnership will help introduce Biocytogen’s innovative animal models and its world-class antibody drug research capabilities to Japanese customers in various therapeutic fields including but not limited to immuno-oncology and auto-immune diseases. Under the agreement, INA represents Biocytogen as a sales agent and distributor to promote Biocytogen’s animal models and research services and capabilities in Japan.

“As both INA and Biocytogen having a strong focus on supporting pharmaceutical partner’s development on novel therapeutics, each has strength at different drug development stages. Therefore, the partnership would be a perfect match and create added value. By working as a team, we can provide a streamlined drug discovery and development platform to our business in Japan.” said Yuelei Shen, Ph.D., president and CEO of Biocytogen.

“We feel the thriving demand in Japan for animal models and non-clinical in vivo drug efficacy evaluation services, especially in the field of immunotherapy. Biocytogen‘s animal models and research capabilities have been recognized by  world-wide customers including top MNCs in US, Europe and China for years and we would love to introduce them into Japan to support our customers and more importantly, to help accelerate drug innovation here in Japan.” said Kenshi Nakagawa, president and CEO of INA.

The partnership gives Biocytogen immediate access to INA’s well-established Japanese customer network including top pharmas, biotechs and institutes in the country. To fulfill the agreement, INA has already hosted a webinar in early October and will launch more events and campaigns to raise awareness of the models and services provided by its newly forged partner, Biocytogen.

Company Profile

About Beijing Biocytogen Co., Ltd.

Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to the patients around the world as its mission. Biocytogen has established a highly integrated antibody drug discovery platform based on a series of genetically-modified animal models. Biocytogen has developed the RenMabTM mouse model for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity.

Biocytogen has launched a pioneering antibody drug development plan (Project Integrum https://biocytogen.com/renmab-mouse/project-integrum/) to tackle difficult targets based on the immunization of RenMabTM knockout mice. Nearly 1,500 targets knockout mouse strains will be generated within 2 years for antibody discovery. Moreover, with the knockout immunization strategy, antibody hits cross-reacting with different species shall be more likely to be generated for better translational efficacy and toxicity evaluation.

With the world-class expertise in genetically-engineered animal development and maintenance with large-scale animal breeding capacity, antibody discovery, and preclinical pharmacology services, the company provides seamless integrated antibody discovery services to the biomedical community for a true one-stop solution from target to IND application and has built its collaboration with more than 2,000 partners worldwide, including over 70% of top 20 MNCs.

About Ina Research Co., Ltd.

Founded in 1974, Ina Research’s headquarters is in the city of Ina, located in the Nagano prefecture, and it operates offices in Tokyo. The firm’s shares are traded publicly on the JASDAQ exchange.

Ina’s scientists primarily conduct analysis and safety and efficacy studies for customers in the pharmaceutical industry, though the organization also works with companies that produce agricultural chemicals and medical equipment.

Research specialties including drug dependence studies, efficacy studies for central nervous system therapies, cancer studies, reproductive and developmental toxicity studies, and animal models.

Ina has established a research center on Ina’s campus under the collaboration with academic institute to conduct non-clinical safety studies for CAR-T therapy, funded by the Japan Agency for Medical Research and Development.